Cabaletta Bio 10-Q: Going-Concern Warning Lifted as Cash Reaches $299.4M
CABA is trading near its 52-week low of $1.32 (12% above the low).
Summary
Cabaletta's Q3 2026 10-Q removes the going-concern warning after warrant exercises and ATM sales pushed cash to $299.4M, funding operations into 1Q28, though the quarterly net loss widened to $53.1M.
Key Events · Earnings and Guidance · CABA
-
Going-Concern Warning Removed
The substantial doubt disclosed in the Q2 2026 10-Q is no longer present, following $115.0M of warrant exercise proceeds and $6.0M of net ATM proceeds in Q3 2026.
-
Cash of $299.4M, Runway to 1Q28
Cash and cash equivalents stood at $299,383 thousand at September 30, 2026 versus $82,982 thousand at December 31, 2025, funding operations into the first quarter of 2028.
-
Q3 Net Loss Widens to $53.1M
Net loss was $53,053 thousand for the quarter and $147,586 thousand for the nine months, with R&D expense of $47,144 thousand versus $39,824 thousand a year earlier.
-
Share Count More Than Doubles
Shares outstanding reached 215,720,392 as of October 30, 2026, up from 100,479,323 at December 31, 2025, after 51,725,000 shares issued in the May 2026 financing and 46,011,900 warrant shares in Q3.
Analysis · CABA · Life Sciences
The going-concern warning that hung over the Q2 2026 10-Q is gone. Warrant exercises of $115.0M plus $6.0M of ATM sales in Q3 lifted cash and equivalents to $299.4M at September 30, 2026, enough to fund operations into the first quarter of 2028. The cost is dilution: shares outstanding rose to 215,720,392 from 100,479,323 at year-end. Losses are still widening, too, with a $53.1M net loss for the quarter. Runway now extends through the adult myositis registrational topline expected in the second half of 2027 and a planned BLA in the first quarter of 2028.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CABA was trading at $1.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $240.8M. The 52-week trading range was $1.32 to $4.23. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.